Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 29 more
Conditions
Chronic Hepatitis, Hepatitis B
Interventions
Clevudine, Adefovir
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Anaheim, California • Fresno, California + 36 more
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Conditions
Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more
Conditions
Hepatitis B Virus Infection
Interventions
GIGA-2339, Placebo
Drug
Lead sponsor
GigaGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Chandler, Arizona • Huntington Beach, California • Lake Forest, California + 9 more
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Conditions
Hepatitis, Hepatitis B, Chronic, Cirrhosis
Interventions
Telbivudine, Lamivudine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 5 more
Conditions
Hepatitis B
Interventions
Entecavir (ETV), Adefovir (ADV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 11 more
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 31 more
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
HIV Infections, Chronic Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more
Conditions
Chronic Hepatitis B
Interventions
Vesatolimod, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis B
Interventions
TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Active, not recruiting Phase 3 Interventional

Entecavir to TAF Switch

NCT03489239
Conditions
Hepatitis B
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, SOC NUC, Placebo Oral Tablet
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 2 more
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Conditions
Hepatitis B
Interventions
Tenofovir & Emtricitabine, Tenofovir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska